Skip to main content
SpringerLink
Log in

Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zu der aktuellen Therapie der neovaskulären AMD Mai 2005

  • Gesellschaftsberichte
  • Published:
Spektrum der Augenheilkunde Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bressler SB, Pieramici DJ, Koester JM, Bressler NM (2004) Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) Investigation: outcomes potentially relevant to management. TAP Report No. 6. Arch Ophthalmol 122: 325–329

    Article  Google Scholar 

  2. Verteporfm Roundtable 2000 and 2001 Participants (2002) Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, Verteporfm In Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfm (Visudyne®) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 22: 6–18

    Article  Google Scholar 

  3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfm: twoyear results of 2 randomized clinical trials-TAP Report 2. Arch Ophthalmol 119: 198–207

    Google Scholar 

  4. Verteporfm In Photodynamic Therapy (VIP) Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization —Verteporfm In Photodynamic Therapy Report 2. Am J Ophthalmol 131: 541–560

    Article  Google Scholar 

  5. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfm In Photodynamic Therapy (VIP) Study Groups (2003) Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfm therapy for choroidal neovascularization secondary to age-related macular degeneration-TAP and VIP Report No. 1. Am J Ophthalmol 136: 407–418

    Article  Google Scholar 

  6. Rosenfeld PJ, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Visual outcomes in patients with minimally classic choroidal neovascularization (CNV): rationale for the Visudyne In Minimally classic CNV (VIM) Trial. Invest Ophthalmol Vis Sci 42: 512

    Google Scholar 

  7. Danis RP, Ciulla TA, Pratt LM, Anliker W (2000) Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20: 244–250

    Article  CAS  Google Scholar 

  8. Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W et al (2003) A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 121: 667–673

    Article  CAS  Google Scholar 

  9. Jonas JB, Degenring RF, Kreissig I, Friedemann T, Akkoyun I (2004) Exudative agerelated macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye

  10. Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfm and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110: 1517–1525

    Article  Google Scholar 

  11. Rechtman E, Danis RP, Pratt LM, Harris A (2004) Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 88: 344–347

    Article  CAS  Google Scholar 

  12. Gragoudas ES (2004) VEGF inhibition study in ocular neovascularization-1 (V1SION-1): Efficacy results from phase II/III Macugen (pegaptanib sodium) clinical trials. Invest Ophthalmol Vis Sci E-Abstract 2364

  13. Schwartz SD (2004) Anti-VEGF:Eyetech-Macugen. Data taken from presentation at 2004 AAO Retina Subspeciality Day

  14. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR (2004) VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 30; 351: 2805–16

    Article  Google Scholar 

  15. Heier JS (2004) Review of Lucentis™ (ranibizumab, rhuFab V2) phase I/II trial results: 6-month treatment of exudative AMD. Invest Ophthalmol Vis Sci E-Abstract 1109

  16. Anecortave Acetate Clinical Study Group (2003) Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 10: 2372–2383

    Google Scholar 

  17. Slakter JS, Anecortave Acetate Clinical Study Group (2004) Anecortave Acetate in the treatment of Age-Related Macular Degeneration (AMD). Invest Ophthalmol Vis Sci E-Abstract 1110

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zu der aktuellen Therapie der neovaskulären AMD Mai 2005. Spektrum Augeheilkd 19, 242–248 (2005). https://doi.org/10.1007/BF03163406

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03163406

Search

Navigation